Literature DB >> 30130452

Update of humanized animal disease models in studying Graft-versus-host disease.

Feng Huang1, Feng Lin Cao2, Song Guo Zheng3.   

Abstract

Graft-versus-host disease (GVHD) is a severe adverse effect that results from bone marrow or peripheral blood cells transplantation and has a high rate of mortality. About 50% of the patients are accompanied with acute Graft-versus-Host Disease (aGVHD) after bone marrow cell transplantation and need systematic treatment. It has an important clinical significance to evaluate the prevention and treatment effects of GVHD. The stable and reliable approaches of humanized animal models are crucial for advancing on the study the biology of GVHD. Relative models transplanting the human immune cells into the mouse body can trigger immunoreaction similar to the humans. As it is a disease triggered by human immune cells, any intervention research prior to clinical treatment has more clinical interrelations compared with the general animal models. In this review, we update the current understanding on humanized animal disease models on studying Graft-versus-host disease and expect to provide more theoretical basis to further study on Graft-versus-host disease.

Entities:  

Keywords:  Autoimmune diseases; Graft-versus-host disease; Humanized animal models; NOG-SCID mice

Mesh:

Year:  2018        PMID: 30130452      PMCID: PMC6314410          DOI: 10.1080/21645515.2018.1512454

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  61 in total

1.  Human-pig spleen transplantation leading to high level of chimerism.

Authors:  Y Li; K Wang; J Cheng; F Li; Y Ma; Y Yang
Journal:  Transplant Proc       Date:  2000-08       Impact factor: 1.066

Review 2.  Acute graft-vs-host disease: pathobiology and management.

Authors:  H Goker; I C Haznedaroglu; N J Chao
Journal:  Exp Hematol       Date:  2001-03       Impact factor: 3.084

3.  TGF-β-induced CD4+Foxp3+ T cells attenuate acute graft-versus-host disease by suppressing expansion and killing of effector CD8+ cells.

Authors:  Jian Gu; Ling Lu; Maogen Chen; Lili Xu; Qin Lan; Qiang Li; Zhongmin Liu; Guihua Chen; Ping Wang; Xuehao Wang; David Brand; Nancy Olsen; Song Guo Zheng
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

4.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 5.  Current advances in humanized mouse models.

Authors:  Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

Review 6.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

7.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

8.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

Authors:  J M McCune; R Namikawa; H Kaneshima; L D Shultz; M Lieberman; I L Weissman
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

9.  Peripheral blood leukocyte grafts that induce human to mouse graft-vs.-host disease reject allogeneic human skin grafts.

Authors:  W Huppes; G Hoffmann-Fezer
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 10.  The human immune system in hu-PBL-SCID mice.

Authors:  M Tary-Lehmann; A Saxon; P V Lehmann
Journal:  Immunol Today       Date:  1995-11
View more
  2 in total

1.  IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model.

Authors:  Cuiping Zhang; Mina Delawary; Peng Huang; Jennifer A Korchak; Koji Suda; Abba C Zubair
Journal:  Cells       Date:  2021-11-10       Impact factor: 6.600

2.  Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers.

Authors:  Yan-Ruide Li; Samuel Zeng; Zachary Spencer Dunn; Yang Zhou; Zhe Li; Jiaji Yu; Yu-Chen Wang; Josh Ku; Noah Cook; Adam Kramer; Lili Yang
Journal:  iScience       Date:  2022-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.